Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 2 (2005), Issue 6 (June)

1. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases.
   J Natl Cancer Inst, 97(11): 798-804. [Abstract] [Full-text]
2. Androgen receptor regulates Cdc6 in synchronized LNCaP cells progressing from G1 to S phase.
   J Cell Physiol, 204(2): 381-7. [Abstract] [Full-text]
3. Assessment of a fragment of e-cadherin as a serum biomarker with predictive value for prostate cancer.
   Br J Cancer, 92(11): 2018-23. [Abstract] [Full-text]
4. Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme.
   Prostate Cancer Prostatic Dis, 8(2): 194-200. [Abstract] [Full-text]
5. Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer.
   Clin Cancer Res, 11(11): 4117-27. [Abstract] [Full-text]
6. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci.
   Clin Cancer Res, 11(11): 4097-106. [Abstract] [Full-text]
7. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy.
   Clin Cancer Res, 11(11): 4037-43. [Abstract] [Full-text]
8. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer.
   Clin Cancer Res, 11(11): 4022-8. [Abstract] [Full-text]
9. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
   Cancer Res, 65(11): 4902-8. [Abstract] [Full-text]
10. Hyperthermia-induced proteasome inhibition and loss of androgen receptor expression in human prostate cancer cells.
    Cancer Res, 65(11): 4836-43. [Abstract] [Full-text]
11. CCAAT/enhancer-binding protein delta: a molecular target of 1,25-dihydroxyvitamin D3 in androgen-responsive prostate cancer LNCaP cells.
    Cancer Res, 65(11): 4762-8. [Abstract] [Full-text]
12. EphB4 expression and biological significance in prostate cancer.
    Cancer Res, 65(11): 4623-32. [Abstract] [Full-text]
13. PCOTH, a novel gene overexpressed in prostate cancers, promotes prostate cancer cell growth through phosphorylation of oncoprotein TAF-Ibeta/SET.
    Cancer Res, 65(11): 4578-86. [Abstract] [Full-text]
14. Evaluating the use of early hormonal therapy in patients with localised or locally advanced prostate cancer.
    Prostate Cancer Prostatic Dis, 8(2): 140-51. [Abstract] [Full-text]
15. Sociodemographic factors associated with postprostatectomy radiotherapy.
    Prostate Cancer Prostatic Dis, 8(2): 184-8. [Abstract] [Full-text]
16. The relationship between the androgen receptor CAG repeat polymorphism length and the response to intermittent androgen suppression therapy for advanced prostate cancer.
    Prostate Cancer Prostatic Dis, 8(2): 179-83. [Abstract] [Full-text]
17. Wnt signalling and prostate cancer.
    Prostate Cancer Prostatic Dis, 8(2): 119-26. [Abstract] [Full-text]
18. PSA recurrence following radical prostatectomy is comparable for all age groups in the UK.
    Prostate Cancer Prostatic Dis, 8(2): 158-62. [Abstract] [Full-text]
19. Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by raloxifene, an antiestrogen with anti-androgen action, but not nimesulide, a selective cyclooxygenase-2 inhibitor.
    Carcinogenesis, 26(6): 1109-16. [Abstract] [Full-text]
20. The emerging role of the PI3-K-Akt pathway in prostate cancer progression.
    Prostate Cancer Prostatic Dis, 8(2): 108-18. [Abstract] [Full-text]
21. Nerve-sparing radical retropubic prostatectomy: techniques and clinical considerations.
    Prostate Cancer Prostatic Dis, 8(2): 133-9. [Abstract] [Full-text]
22. Long-term outcome of detectable PSA levels after radical prostatectomy.
    Prostate Cancer Prostatic Dis, 8(2): 163-6. [Abstract] [Full-text]
23. What is the best postoperative treatment for patients with pT3bN0M0 adenocarcinoma of the prostate?
    Prostate Cancer Prostatic Dis, 8(2): 167-73. [Abstract] [Full-text]
24. Effects of androgen suppression and radiation on prostate cancer suggest a role for angiogenesis blockade.
    Prostate Cancer Prostatic Dis, 8(2): 127-32. [Abstract] [Full-text]
25. Prostate cancer relapse after therapy with curative intention: a diagnostic and therapeutic dilemma.
    Onkologie, 28(6): 361-6. [Abstract] [Full-text]
26. Australia-wide comparison of intensity modulated radiation therapy prostate plans.
    Australas Radiol, 49(3): 222-9. [Abstract] [Full-text]
27. Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells.
    Cell Death Differ, 12(5): 482-91. [Abstract] [Full-text]
28. Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype.
    Prostate, 63(4): 369-84. [Abstract] [Full-text]
29. Obesity before age 30 years and risk of advanced prostate cancer.
    Am J Epidemiol, 161(12): 1107-14. [Abstract] [Full-text]
30. Acne in adolescence and cause-specific mortality: lower coronary heart disease but higher prostate cancer mortality: the Glasgow Alumni Cohort Study.
    Am J Epidemiol, 161(12): 1094-101. [Abstract] [Full-text]
31. Localization of linked 125I seeds in postimplant TRUS images for prostate brachytherapy dosimetry.
    Int J Radiat Oncol Biol Phys, 62(3): 912-9. [Abstract] [Full-text]
32. Effect of androgen suppression on hemoglobin in prostate cancer patients undergoing salvage radiotherapy plus 2-year buserelin acetate for rising PSA after surgery.
    Int J Radiat Oncol Biol Phys, 62(3): 719-24. [Abstract] [Full-text]
33. PSA bounces after neoadjuvant androgen deprivation and external beam radiation: impact on definitions of failure.
    Int J Radiat Oncol Biol Phys, 62(3): 714-8. [Abstract] [Full-text]
34. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
    Int J Radiat Oncol Biol Phys, 62(3): 706-13. [Abstract] [Full-text]
35. Opacity transfer function optimization for volume-rendered computed tomography images of the prostate.
    Acad Radiol, 12(6): 761-70. [Abstract] [Full-text]
36. A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer.
    Cancer Chemother Pharmacol, 56(2): 199-204. [Abstract] [Full-text]
37. Carcinosarcoma of the prostate: two cases with distinctive morphologic and immunohistochemical findings.
    Virchows Arch, 446(5): 511-6. [Abstract] [Full-text]
38. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer.
    J Biol Chem, 280(23): 22437-44. [Abstract] [Full-text]
39. Down-regulation of BRCA2 expression by collagen type I promotes prostate cancer cell proliferation.
    J Biol Chem, 280(23): 22482-91. [Abstract] [Full-text]
40. Androgen receptor mutants detected in recurrent prostate cancer exhibit diverse functional characteristics.
    Prostate, 63(4): 395-406. [Abstract] [Full-text]
41. In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines.
    Prostate, 63(4): 385-94. [Abstract] [Full-text]
42. Perineural invasion in prostate cancer biopsies is not associated with higher rates of positive surgical margins.
    Prostate, 63(4): 336-40. [Abstract] [Full-text]
43. Quantitative and immunohistochemical evaluation of PCNA, androgen receptors, apoptosis, and Glutathione-S-Transferase P1 on preneoplastic changes induced by cadmium and zinc chloride in the rat ventral prostate.
    Prostate, 63(4): 347-57. [Abstract] [Full-text]
44. Alpha-methylacyl-CoA racemase (AMACR) expression in normal prostatic glands and high-grade prostatic intraepithelial neoplasia (HGPIN): association with diagnosis of prostate cancer.
    Prostate, 63(4): 341-6. [Abstract] [Full-text]
45. Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer.
    Prostate, 63(4): 316-23. [Abstract] [Full-text]
46. Polymorphic forms of prostate specific antigen and their interaction with androgen receptor trinucleotide repeats in prostate cancer.
    Prostate, 63(4): 309-15. [Abstract] [Full-text]
47. Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue.
    Prostate, 63(4): 324-9. [Abstract] [Full-text]
48. A pilot study to determine support during the pre-treatment phase of early prostate cancer.
    Psychooncology, 14(6): 442-9. [Abstract] [Full-text]
49. A novel acylglycerol kinase that produces lysophosphatidic acid modulates cross talk with EGFR in prostate cancer cells.
    J Cell Biol, 169(5): 801-11. [Abstract] [Full-text]
50. An interdisciplinary approach to treating prostate cancer.
    Urology, 65(6): 13-8. [Abstract] [Full-text]
51. Future directions in the treatment of androgen-independent prostate cancer.
    Urology, 65(6): 8-12. [Abstract] [Full-text]
52. The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer.
    Urology, 65(6): 2-7. [Abstract] [Full-text]
53. Tumour-suppression activity of the proapoptotic regulator Par4.
    EMBO Rep, 6(6): 577-83. [Abstract] [Full-text]
54. Prediagnostic plasma vascular endothelial growth factor levels and risk of prostate cancer.
    Cancer Epidemiol Biomarkers Prev, 14(6): 1557-61. [Abstract] [Full-text]
55. Physical activity and the risk of prostate cancer in the Netherlands cohort study, results after 9.3 years of follow-up.
    Cancer Epidemiol Biomarkers Prev, 14(6): 1490-5. [Abstract] [Full-text]
56. Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death.
    Cancer Epidemiol Biomarkers Prev, 14(6): 1424-32. [Abstract] [Full-text]
57. 70 Gy or more: which dose for which prostate cancer?
    J Cancer Res Clin Oncol, 131(7): 407-19. [Abstract] [Full-text]
58. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Cancer, 103(12): 2499-506. [Abstract] [Full-text]
59. Predictor of response to salvage radiotherapy in patients with PSA recurrence after radical prostatectomy: the usefulness of PSA doubling time.
    Jpn J Clin Oncol, 35(5): 256-9. [Abstract] [Full-text]
60. Regulation of androgen receptor levels: implications for prostate cancer progression and therapy.
    J Cell Biochem, 95(4): 657-69. [Abstract] [Full-text]
61. Problem-solving and distress in prostate cancer patients and their spousal caregivers.
    Support Care Cancer, 13(6): 367-74. [Abstract] [Full-text]
62. Influence of neuroendocrine tumor cells on proliferation in prostatic carcinoma.
    Hum Pathol, 36(5): 562-70. [Abstract] [Full-text]
63. The utility of Ki-67 expression in the differential diagnosis of prostatic intraepithelial neoplasia and ductal adenocarcinoma.
    Hum Pathol, 36(5): 531-5. [Abstract] [Full-text]
64. Alcohol drinking and risk of localized versus advanced and sporadic versus familial prostate cancer in Sweden.
    Cancer Causes Control, 16(3): 275-84. [Abstract] [Full-text]
65. Sexually transmitted diseases and other urogenital conditions as risk factors for prostate cancer: a case--control study in Wayne County, Michigan.
    Cancer Causes Control, 16(3): 263-73. [Abstract] [Full-text]
66. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era.
    Cancer Causes Control, 16(3): 255-62. [Abstract] [Full-text]
67. Evidence for specific TRPM8 expression in human prostate secretory epithelial cells: functional androgen receptor requirement.
    Endocr Relat Cancer, 12(2): 367-82. [Abstract] [Full-text]
68. Identification of growth factor independent-1 (GFI1) as a repressor of 25-hydroxyvitamin D 1-alpha hydroxylase (CYP27B1) gene expression in human prostate cancer cells.
    Endocr Relat Cancer, 12(2): 351-65. [Abstract] [Full-text]
69. Alterations in the regulatory volume decrease (RVD) and swelling-activated Cl- current associated with neuroendocrine differentiation of prostate cancer epithelial cells.
    Endocr Relat Cancer, 12(2): 335-49. [Abstract] [Full-text]
70. Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours.
    Endocr Relat Cancer, 12(2): 229-44. [Abstract] [Full-text]
71. Reduction in uptake of PSA tests following decision aids: systematic review of current aids and their evaluations.
    Patient Educ Couns, 58(1): 13-26. [Abstract] [Full-text]
72. Role of lycopene and tomato products in prostate health.
    Biochim Biophys Acta, 1740(2): 202-5. [Abstract] [Full-text]
73. Different effect of beta-carotene on proliferation of prostate cancer cells.
    Biochim Biophys Acta, 1740(2): 189-201. [Abstract] [Full-text]
74. Obesity and prostate cancer screening in the USA.
    Public Health, 119(8): 694-8. [Abstract] [Full-text]
75. Predictors of prostate cancer screening among health fair participants.
    Public Health, 119(8): 686-93. [Abstract] [Full-text]
76. Differently regulated androgen receptor transcriptional complex in prostate cancer compared with normal prostate.
    Int J Urol, 12(4): 390-7. [Abstract] [Full-text]
77. The possibility of 'de novo' cancer in the prostate.
    Int J Urol, 12(4): 361-4. [Abstract] [Full-text]
78. Efficacy and morbidity of transrectal ultrasound-guided 12-core biopsy for detection of prostate cancer in Japanese men.
    Int J Urol, 12(4): 353-60. [Abstract] [Full-text]
79. Determination of the relative probability for prostate cancer to avoid unnecessary biopsy.
    Int J Urol, 12(4): 346-52. [Abstract] [Full-text]
80. Apoptosis in prostate cancer: bax correlation with stage.
    Int J Urol, 12(4): 340-5. [Abstract] [Full-text]
81. A new class of inhibitors of 2-arachidonoylglycerol hydrolysis and invasion of prostate cancer cells.
    Biochem Biophys Res Commun, 332(4): 1028-33. [Abstract] [Full-text]
82. Induction of apoptosis in prostate cancer cells by pachymic acid from Poria cocos.
    Biochem Biophys Res Commun, 332(4): 1153-61. [Abstract] [Full-text]
83. Down-regulation of ATM protein sensitizes human prostate cancer cells to radiation-induced apoptosis.
    J Biol Chem, 280(24): 23262-72. [Abstract] [Full-text]
84. Is reduced CAG repeat length in androgen receptor gene associated with risk of prostate cancer in Indian population?
    Clin Genet, 68(1): 55-60. [Abstract] [Full-text]
85. Chromosomal changes in prostate cancer: a fluorescence in situ hybridization study.
    Clin Genet, 68(1): 40-7. [Abstract] [Full-text]
86. Receptor isoform and ligand-specific modulation of dihydrotestosterone-induced prostate specific antigen gene expression and prostate tumor cell growth by estrogens.
    J Androl, 26(4): 500-8; discussion 509-10. [Abstract] [Full-text]
87. Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues.
    Br J Cancer, 92(12): 2171-80. [Abstract] [Full-text]
88. The use of Raman spectroscopy to differentiate between different prostatic adenocarcinoma cell lines.
    Br J Cancer, 92(12): 2166-70. [Abstract] [Full-text]
89. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
    Clin Cancer Res, 11(12): 4512-20. [Abstract] [Full-text]
90. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables.
    Clin Cancer Res, 11(12): 4469-78. [Abstract] [Full-text]
91. Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial.
    Clin Cancer Res, 11(12): 4437-43. [Abstract] [Full-text]
92. Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer.
    Clin Cancer Res, 11(12): 4365-71. [Abstract] [Full-text]
93. Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer.
    Cancer Res, 65(12): 5470-9. [Abstract] [Full-text]
94. The androgen derivative 5alpha-androstane-3beta,17beta-diol inhibits prostate cancer cell migration through activation of the estrogen receptor beta subtype.
    Cancer Res, 65(12): 5445-53. [Abstract] [Full-text]
95. A human- and male-specific protocadherin that acts through the wnt signaling pathway to induce neuroendocrine transdifferentiation of prostate cancer cells.
    Cancer Res, 65(12): 5263-71. [Abstract] [Full-text]
96. Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target.
    Cancer Res, 65(12): 5153-62. [Abstract] [Full-text]
97. Two functional epitopes of pigment epithelial-derived factor block angiogenesis and induce differentiation in prostate cancer.
    Cancer Res, 65(12): 5144-52. [Abstract] [Full-text]
98. Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors.
    Cancer Res, 65(12): 5054-62. [Abstract] [Full-text]
99. Phase II study of prolonged ambulatory infusion carboplatin and oral etoposide for patients progressing through hormonal therapy for prostate cancer.
    Intern Med J, 35(7): 405-8. [Abstract] [Full-text]
100. Endogenous immune response to gangliosides in patients with confined prostate cancer.
     Int J Cancer, 116(3): 368-77. [Abstract] [Full-text]
101. Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination.
     Int J Cancer, 116(3): 415-21. [Abstract] [Full-text]
102. The use of CT-MR image registration to define target volumes in pelvic radiotherapy in the presence of bilateral hip replacements.
     Br J Radiol, 78(931): 634-6. [Abstract] [Full-text]
103. Achieving optimal outcomes after radical prostatectomy.
     J Clin Oncol, 23(18): 4146-51. [Abstract] [Full-text]
104. Implications of spillover effects within the family for medical cost-effectiveness analysis.
     J Health Econ, 24(4): 751-73. [Abstract] [Full-text]
105. Adeno-associated virus 2-mediated intratumoral prostate cancer gene therapy: long-term maspin expression efficiently suppresses tumor growth.
     Hum Gene Ther, 16(6): 699-710. [Abstract] [Full-text]
106. Extracorporeal application of high-intensity focused ultrasound for prostatic tissue ablation.
     BJU Int, 96(1): 71-6. [Abstract] [Full-text]
107. The relationship between angiogenesis and cyclooxygenase-2 expression in prostate cancer.
     BJU Int, 96(1): 62-6. [Abstract] [Full-text]
108. Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study.
     BJU Int, 96(1): 48-53. [Abstract] [Full-text]
109. Radical prostatectomy versus high-dose rate brachytherapy for prostate cancer: effects on health-related quality of life.
     BJU Int, 96(1): 43-7. [Abstract] [Full-text]
110. Robot-assisted vs pure laparoscopic radical prostatectomy: are there any differences?
     BJU Int, 96(1): 39-42. [Abstract] [Full-text]
111. Installation of telerobotic surgery and initial experience with telerobotic radical prostatectomy.
     BJU Int, 96(1): 34-8. [Abstract] [Full-text]
112. Racial differences in serum prostate-specific antigen (PSA) doubling time, histopathological variables and long-term PSA recurrence between African-American and white American men undergoing radical prostatectomy for clinically localized prostate cancer.
     BJU Int, 96(1): 29-33. [Abstract] [Full-text]
113. Gefitinib-trastuzumab combination on hormone-refractory prostate cancer xenograft.
     Eur J Cancer, 41(10): 1467-73. [Abstract] [Full-text]
114. Maximum tumor diameter is an independent predictor of prostate-specific antigen recurrence in prostate cancer.
     Mod Pathol, 18(7): 886-90. [Abstract] [Full-text]
115. Evaluation of tumoral enhancement by superparamagnetic iron oxide particles: comparative studies with ferumoxtran and anionic iron oxide nanoparticles.
     Eur Radiol, 15(7): 1369-77. [Abstract] [Full-text]
116. Differentiation of prostate cancer from normal prostate tissue in an animal model: conventional MRI and dynamic contrast-enhanced MRI.
     Rofo, 177(7): 935-9. [Abstract] [Full-text]
117. Psychosocial consequences of prostate cancer: 30 years of research.
     Geriatr Nurs, 26(3): 166-75. [Abstract] [Full-text]
118. Dosimetric impact of image-guided 3D conformal radiation therapy of prostate cancer.
     Phys Med Biol, 50(13): 3083-101. [Abstract] [Full-text]
119. Prostate cancer risk and DNA damage: translational significance of selenium supplementation in a canine model.
     Carcinogenesis, 26(7): 1256-62. [Abstract] [Full-text]
120. The androgen receptor directly targets the cellular Fas/FasL-associated death domain protein-like inhibitory protein gene to promote the androgen-independent growth of prostate cancer cells.
     Mol Endocrinol, 19(7): 1792-802. [Abstract] [Full-text]
121. Prostate carcinogenesis and inflammation: emerging insights.
     Carcinogenesis, 26(7): 1170-81. [Abstract] [Full-text]
122. The presence of benign prostatic glandular tissue at surgical margins does not predict PSA recurrence.
     J Clin Pathol, 58(7): 725-8. [Abstract] [Full-text]
123. Molecular pathology of prostate cancer.
     J Clin Pathol, 58(7): 673-84. [Abstract] [Full-text]
124. Partnership status influences quality of life in low-income, uninsured men with prostate cancer.
     Cancer, 104(1): 191-8. [Abstract] [Full-text]
125. CpG methylation at promoter site -140 inactivates TGFbeta2 receptor gene in prostate cancer.
     Cancer, 104(1): 44-52. [Abstract] [Full-text]
126. CYP3A5 gene polymorphism and risk of prostate cancer in a Japanese population.
     Cancer Lett, 225(2): 237-43. [Abstract] [Full-text]
127. Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice.
     J Biol Chem, 280(26): 25134-45. [Abstract] [Full-text]
128. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
     Prostate, 64(3): 303-15. [Abstract] [Full-text]
129. pH modulation using CsCl enhances therapeutic effects of vitamin D in LNCaP tumor bearing mice.
     Prostate, 64(3): 316-22. [Abstract] [Full-text]
130. Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo.
     Prostate, 64(3): 293-302. [Abstract] [Full-text]
131. Magnetic fluid hyperthermia (MFH)reduces prostate cancer growth in the orthotopic Dunning R3327 rat model.
     Prostate, 64(3): 283-92. [Abstract] [Full-text]
132. Acetylation genotype and the genetic susceptibility to prostate cancer in a southern European population.
     Prostate, 64(3): 246-52. [Abstract] [Full-text]
133. Sequence variation within the 5' regulatory regions of the vitamin D binding protein and receptor genes and prostate cancer risk.
     Prostate, 64(3): 272-82. [Abstract] [Full-text]
134. Loss of heterozygosity on chromosome 2 in Japanese patients with prostate cancer.
     Prostate, 64(3): 265-71. [Abstract] [Full-text]
135. Risk stratification after radical prostatectomy in men with pathologically organ-confined prostate cancer using volume-weighted mean nuclear volume.
     Prostate, 64(3): 217-23. [Abstract] [Full-text]
136. Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk.
     Prostate, 64(3): 240-5. [Abstract] [Full-text]
137. Constitutive activation of P I3 K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model.
     Prostate, 64(3): 224-39. [Abstract] [Full-text]
138. Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature.
     Histopathology, 47(1): 1-16. [Abstract] [Full-text]
139. Role of mitogen-activated protein kinases in phenethyl isothiocyanate-induced apoptosis in human prostate cancer cells.
     Mol Carcinog, 43(3): 130-40. [Abstract] [Full-text]
140. Global histone modification patterns predict risk of prostate cancer recurrence.
     Nature, 435(7046): 1262-6. [Abstract] [Full-text]
141. Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells.
     Mol Cell Biol, 25(14): 6279-88. [Abstract] [Full-text]
142. Prostate cancer: precision of integrating functional MR imaging with radiation therapy treatment by using fiducial gold markers.
     Radiology, 236(1): 311-7. [Abstract] [Full-text]
143. Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models.
     Cancer Chemother Pharmacol, 56(3): 239-47. [Abstract] [Full-text]
144. Suppression of NF-kappaB and NF-kappaB-regulated gene expression by sulforaphane and PEITC through IkappaBalpha, IKK pathway in human prostate cancer PC-3 cells.
     Oncogene, 24(28): 4486-95. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.